Truth Hurts: DNA Testing Kits Have Recessive Holiday Period

Have concerns about privacy caught up with at-home DNA testing kit companies?

I just took a DNA test; turns out, I’m 100% data-driven.

While DNA tests topped charts in 2019 with a featured line in Lizzo’s hit song Truth Hurts, sales of DNA testing kits, such as those sold by 23andMe and Ancestry DNA, appeared to slow significantly this past holiday season based on M Science’s analysis.

In recent years, these companies have attempted to reach outside the genealogically minded market by expanding their offerings to "genetic health risk reports" that use genetic markers to assess predisposition to hereditary conditions such as Alzheimer's and type-2 diabetes. Concerns over privacy however may be overshadowing the promise of genetically driven health reports with actionable insights.

Although 23andMe reported that personally identifying information would not be shared, mid-2018's announcement of a collaboration with GlaxoSmithKline was met with shock and surprise by many customers who did not realize that their data would be shared with pharmaceutical companies.

This backlash, along with the DNA-driven downfall of the Golden State Killer and December 2019 report that the Pentagon has discouraged defense personnel from purchasing home DNA tests, underscores growing national awareness and concerns about not only privacy and ownership of digital data but of genetic data as well.

While it's difficult to judge intent, M Science’s analysis indicates a clear picture: fewer people appear to have bought DNA kits this past Black Friday, especially from direct-to-consumer channels. Third-party sales and general web interest in these companies have also been seen to decline significantly in M Science’s analysis (based on data sources available to M Science).

As of 2019, 23andMe and Ancestry DNA have reported that the companies have over 10 and 15 million customers, respectively. Although most customers will only ever need to buy one DNA kit in their lifetime, the addressable market for these kits could potentially be anyone with a genome. While we are still far away from a GATTACA-style, genetically-engineered future, it seems certain that DNA testing (and accompanying debates) will only continue to gain relevance as the technologies progress.

Alternative data is in our DNA! For custom and competitive business analysis, please reach out to insights@mscience.com to stay up to date on company- and industry-level trends.

All material contained in this Insights post is the property of M Science LLC or its affiliates unless otherwise indicated. All trademarks, service marks, logos and trade names used in this post are proprietary to M Science or other respective owners. This M Science Insights post is intended for informational purposes only. This post is dated as of the date of publication. M Science undertakes no obligation to update this post. Under no circumstances is this post to be considered as an offer to sell or solicitation of an offer to buy any securities of any company. It should not be assumed that recommendations made in the future will be profitable or will equal the performance of previous recommendations. Comparisons of M Science published estimates to reported results are available by emailing info@mscience.com. M Science provides the information and data contained herein on an “as is,” “as available” basis, without representations or warranties of any

@MScienceLLC